HGV感染在慢性乙型肝炎抗乙肝胎盘肽治疗远期疗效及预后中的意义

目的　探讨庚型肝炎病毒 (HGV)感染对慢性乙型肝炎 (CHB)抗乙肝胎盘治疗的远期疗效及预后的影响。方法　对比观察经肝穿活检确诊 (G2 ～G3)的 11例合并与 2 2例未合并HGV感染的CHB抗乙肝胎盘肽治疗 (4ml,1次 /d ,肌注 ,疗程 4月 )的远期疗效及预后。两组患者在年龄、性别、病程、肝脏损害等方面具有可比性 ,且血清HBsAg ,HBeAg ,HBV DNA均阳性 ,ALT异常。结果　两组患者无论治疗结束时 ,治疗后 6个月、1年、2年ALT复常率、HBeAg ,HBV DNA阴转率 ,还是治疗结束时、治疗后 6个月、1年血清HBV DNA含量变化均无显著差异 (P >0 .0 5 )。 2年后肝功能水平变化也无显著性差别 (P >0 .0 5 )。抗乙肝胎盘肽治疗的 2年持续应答率达 42 4%。结论　HGV感染并不影响CHB抗乙肝胎盘肽治疗的远期疗效 ,也不影响CHB的预后。HGV至多仅有微弱的肝脏致病性。抗乙肝胎盘肽是一种有效的抗乙肝病毒药物。

The role of hepatitis G virus infection in prognosis and long-term efficacy of anti-hepatitis B placental polypeptide treatment of patients with chronic hepatitis B

Objective To explore the effect of hepatitis G virus(HGV)infection on prognosis and long term efficacy of anti hepatitis B placental polypeptide(AHBPP)treatment(4 ml, qd, im, for 4 months)of patients with chronic hepatitis B(CHB). Methods The prognosis and long term efficacy of AHBPP treatment of 11 cases of CHB with serum HGV RNA positive were compared with those of 22 cases of CHB with serum HGV RNA negative, respectively. The two groups were comparable in their age, sex, course of disease and liver lesions. All patients had serum positive of HBsAg, HBeAg, HBV DNA and ALT abnormality. Results There were no significant difference not only in the rate of ALT normality, HBeAg, HBV DNA disappearance at the completion of therapy, 6 months, 12 months, and 24 months after their termination of therapy( P >0.05), but also the amount changes of serum HBV DNA at the completion of therapy, 6 months and 12 months after their termination of therpay( P >0.05). There were no significant difference in liver function level changes after 2 years between the two groups, either( P >0.05). The rate of 2 years continuous response to AHBPP therapy was 42.4%. Conclusions HGV infection does not affect the prognosis and long term efficacy of AHBPP treatment of patients with CHB. The hepatic pathognicity is at most mild for HGV. AHBPP is an effective anti hepatitis B virus drug.